Sciences Seminar Series
Bioassay-Directed Chemical Analysis
Dr. Shane Que Hee
UCLA, Department of Environmental Health Sciences
Shane Que Hee, Professor,
Department of Environmental Health Sciences and
UCLA Center for Occupational and Environmental Health, UCLA School
Public Health, 650 Charles Young Jr Drive, Los Angeles CA
90095-1772; Phone: (310)206-7388; Fax: (310)794-2106; E Mail:
There are millions of molecules
of different types that could be analyzed for contamination and
pollution of environmental and biological media. It does not
make much economic sense to try to analyze for every chemical
species that might be in a given sample if human health or ecological
health are to be protected since only toxic samples need be analyzed
exhaustively. This seminar discusses some of the author's research
and the literature involved in using screening bioassays to identify
toxic components in complex mixtures as well as the spectroscopic
techniques and sample subfractionation or cleanup that must also
be used for toxin isolation, identification and quantification.
In particular, the use of light emitting systems based on bioluminescence
(Vibrio fischeri) for acute and subchronic toxicity, and back
reverting dark mutants to detect genotoxins will be emphasized.
1. SH Yim, SS Que Hee. Bacterial mutagenicity of some tobacco
nitrogen bases and their mixtures. Mutat Res: Gen Toxicol Environ
492: 13-27, 2001.
2. SH Yim, SS Que Hee. Genotoxicity of nicotine and cotinine
bacterial luminescence test. Mutat Res 335: 275-283, 1996.
3. HF Chen, SS Que Hee. Ketone EC50 values in the Microtox test.
Ecotoxicol Environ Safety 30: 120-123, 1995.
4. CC Chou, SS Que Hee. Saliva-available carbonyl compounds in
chewing tobaccos. J Agr Food Chem 42: 2225-2230, 1994.
5. MA Newman, BG Valanis, RS Schoeny, SS Que Hee. Urinary biological
monitoring markers of anticancer drug exposure in oncology nurses.
Public Health 84: 852-855, 1994.
6. R Boucher, GK Livingstone, SS Que Hee. In-vitro micronucleus
of human peripheral lymphocytes for adriamycin in the presence
cyclophosphamide and urines of patients administered anticancer
drugs. Environ Molec Mutagen 21: 372-382, 1993.
7. CC Chou, SS Que Hee. Separation of pH, dilution, ionic strength
chemical matrix effects for biological monitoring ofnurines using
cotinine, and reference urines. J Biochem Chemilum 8: 39-48,
8. CC Chou, SS Que Hee. Microtox EC50 values for drinking water
produced by ozonolysis. Ecotoxicol Environ Safety 23: 355-363,
9. MA Newman, SS Que Hee, RS Schoeny. Mutagenesis assays on urines
produced by patients administered adriamycin and cyclophosphamide.
Molec Mutagen 16: 189-203, 1990.
10. MA Newman, SS Que Hee, RS Schoeny, L Lowry. Biological monitoring
screening of patients provided antineoplastic drugs including
cyclophosphamide, 5-fluorouracil, methotrexate, and vincristine.
res 50: 3351-3366, 1990.
11. AK Giri, SS Que Hee. In-vivo sister chromatid exchange induced
1,2-dichloroethane on bone marrow cells of mice. Environ Molec
Investigations Into the Biochemistry
of Gene Silencing in Arabidopsis
CSULA Bridges to the Ph.D. Scholar
Cell-Specific Expression and
Potential Roles of Cyclic GMP-Dependent
Protein Kinase I in the Rat Ovary
CSULA MBRS-RISE Graduate Scholar
| April 25
Interactive Effects of Stress,
Estrogen and Sex on
Nueral and Cognitive Function
Dr. Victoria Luine
College, City University of NY, Department of Psychology
Interactive effects of stress,
estrogen and sex on neural and cognitive function. Victoria Luine,
Dept. of Psychology, Hunter College of CUNY.Spring 2003.
Recent studies indicate that
steroid hormones of adrenal and gonadal origin influence cognitive
function in animal models and in humans. Corticosterone, released
by stress, impairs cognitive function when stress
is chronic. On the other hand, estradiol promotes cognitive function
in females with low levels of circulating gonadal hormones. Using
a variety of visual and place memory tasks, the effects of altered
steroid hormone levels in male and female rats will be presented.
Under chronic stress (21 days of daily restraint),performance
of males on all tasks was impaired while performance of females
was either enhanced (spatial memory tasks) or not impaired (visual
memory task). Activity of monoamines was also measured in areas
contributing to memory frontal cortex, hippocampus and
amygdala. Sexually dimorphic changes, which may underlie cognitive
effects, were noted in dopamine and serotonin. Finally, the role
of estrogen as a possible neuroprotectant during stress and in
activating neurons responsible for cognitive function will be
presented. Thus, our behavioral and neurochemical results support
the hypothesis that differences/alterations in
steroid hormones which occur as a result of stress, aging and/or
disease exert effects on cognition over the lifespan. Moreover,
sex or gender appears to be a critical determinant of the nature
of the effects.
Recent Review: RE Bowman, KD Beck and VN Luine, Chronic stress
effects on memory: sex differences in performance and monoaminergic
activity. Hormonesand Behavior 43: 48-59 (2003).
Studying Alzheimer's Diesease
Dr. Frank LaFerla
UC Irvine Department of NeurobiologyWebsite:
Abstract: The neuropathological
correlates of Alzheimer's disease (AD) include amyloid-ß
(Aß) plaques and neurofibrillary tangles. To recapitulate
these features, we derived a triple transgenic model (3xTg-AD)
harboring three mutant transgenes: PS1M146V, APPSwe, and tauP301L.
Rather than crossing independent lines, we microinjected two
transgenes into single-cell embryos from homozygous PS1M146V
knockin mice, generating mice with the same genetic background.
3xTg-AD mice progressively develop Aß and tau
pathologies, consistent with the distribution found in the human
AD brain. Here we report that synaptic dysfunction, including
LTP deficits, manifests in an age-related manner, but before
plaque and tangle pathology. The synaptic dysfunction appears
to be due to intraneuronal Aß, as PS1M146V/tauP301L transgenic
mice do not show LTP deficits. These studies suggest a pathogenic
role for intracellular Aß with regards to synaptic activity.
The recapitulation of salient features of AD in these mice clarifies
the relationships between Aß, synaptic dysfunction, and
tangles, and provides a valuable model for testing potential
AD therapeutics as the impact on both lesions can be assessed.
Email Address: email@example.com
Mailing Address: University of California, Irvine
Neurobiology & Behavior
Irvine, CA 92697-4545
Title: Associate Professor
Department: Neurobiology & Behavior
Office Address: 1109 Gillespie Neuroscience Research Facility
Zot Code: 4545
Phone: (949) 824-1232
Fax Number: (949) 824-7356
Other Info: Lab address: 1216 Gillespie Neuroscience Lab phone:
| May 9
Leon Pape Lecture
| May 16
Ethnic Identity: Conceptualization and
Dr. Jean Phinney
CSULA Department of Psychology
The Risk of Osteoporosis in
Mexican American Women: Lifestyle and Physiological Determinants
Noe C. Crespo
MBRS-RISE Graduate Scholar
Urban Pollutant Gradient on a Fine Spatial Scale
CSULA MARC Scholar
Characterization of the Regulatory Role
of Arginine 226
of Maize PEP Caboxylase
CSULA MBRS-RISE Undergraduate Scholar
The Experience of Stress in First Year College Students:
A New Approach to an Old Problem
CSULA MBRS-RISE Graduate Scholar
| June 6
Research, the Academy and Being
a Minority Scientist
(Alderete's Rules for Success)
Department of Microbiology & Immunology
The University of Texas Health Science Center at San Antonio
Brief Biosketch of J. F. Alderete,
John F. Alderete, Ph.D. is
Professor of Microbiology at the University of Texas Health Science
Center at San Antonio, where he has received over $12 million
in research support and over $3 million to support minority organizations
and activities. He was born in Las Vegas, New Mexico in 1950.
He received two B.S. degrees (mathematics and biology) as an
undergraduate student at New Mexico Institute of Mining and Technology
at Socorro. His first and second publications were from work
as an undergraduate with Dr. Gilbert Sanchez at Tech and as a
student intern with Dr. Tom H. Wilson at the Department of Physiology
at Harvard Medical School, respectively. He received his Ph.D.
in microbiology in 1978 from the U. Kansas-Lawrence. He did postdoctoral
work at UNC-Chapel Hill prior to a faculty position at the UT
Health Science Center at San Antonio. He has been director of
two training grants from NIAID/NIH. He has published over 100
publications in peer-review journals and is the author of 31
book chapters and invited OP-ED editorials. His research on sexually
transmitted diseases and on the number one, non-viral sexually
transmitted agent, Trichomonas vaginalis, has been
presented as abstracts published in 117 proceedings of national
and international scientific meetings, where he has also participated
in, chaired, and organized scientific symposia. He has given
over 300 presentations at colleges, universities and conferences
across the country and throughout the world, of which 226 were
seminars on his research work. His research has resulted in 5
patents and 1 patent-pending. His laboratory has submitted 23
sequences to the GenBank database. He has an exclusive license
agreement between the Board of Regents of UT and Xenotope Diagnostics,
Inc. He has been a member of study sections and panels for NIH
institutes, the NSF, USDA and other government agencies. He is
a member of the National Advisory Research Council for the National
Institute of Dental and Craniofacial Research/NIH. Dr. Alderete
served on a National Academy of Sciences Institute of Medicine
panel to examine the Congressionally-mandated request on how
NIH prioritizes its research and was the reviewer of two IOM
panel reports. He serves on three editorial boards and has been
an ad hoc reviewer of 32 scientific journals. He is asked to
speak on issues involving minorities, higher education, and the
scientific workforce by government agencies. These include the
President's National Science Board, the NIH, the Federal FDA,
the White House Office for Science and Technology Policy, and
White House "One Nation" on race and health disparities.
He was asked to moderate the session in October 1999, a Public
Policy Forum on the "Digital Divide" as part of the
President's Information Technology Advisory Committee and The
Woodrow Wilson International Center for Scholars. In April 2000,
he moderated a session at the Office of Research on Minority
Health/NIH conference on health disparities in Washington, DC.
He has received many honors and awards, most notably the Premio
Encuentro Award for Science and Technology in 1992, the single
highest honor given to an Hispanic in America. He was elected
into the honorific societies Sigma _i and as a Fellow of the
American Academy of Microbiology, and in the fall of 2001 was
honored at the National Atomic Museum in New Mexico. Also in
2002, the Spring issue of Hispanic Engineer & Information
Technology magazine honored Dr. Alderete for his efforts
to bridge the "Digital Divide" for minorities, among
other outreach activities. Hispanic Magazine selected him as
one of the 100 Most Influential Hispanics in America. He conducted
for over a ten-year period a Saturday Morning Science Camp for
minority students, parents and teachers, which was adopted by
a community-based organization. He has mentored underrepresented
minorities from undergraduate institutions and high schools as
summer interns in his laboratory. He has given presentations
throughout K-12 schools in the San Antonio and South Texas area.
He has mentored 1 M.S. student, 7 Ph.D. students, 13 postdoctoral
fellows, 7 visiting scientists, 2 M.D. fellows, and 32 minority
high school and undergraduate students. Dr. Alderete is the past-president
of the Society for the Advancement of Chicanos and Native Americans
in the Sciences (SACNAS). More recently, he is co-founder of
a biotechnology company, Xenotope Diagnostics, Inc. (http://www.xenotope.com),
a company that specializes in development of diagnostics for
infectious diseases. The company is FDA-approved for two products
for the diagnosis of STD vaginitis.
For other information on Dr. Alderete, visit the following websites:
NEWS RELEASE: The University of Texas
Health Science Center at San Antonio, January 14, 2003
XENOTOPE AND GENZYME SIGN DEFINITIVE
Xenotope Diagnostics, Inc. and Genzyme
Corporation have signed a definitive agreement whereby Genzyme
is authorized to manufacture a proprietary diagnostic developed
by Xenotope for the detection of Trichomonas Vaginalis,
a sexually transmitted disease (STD). The diagnostic was developed
from research originating from the microbiology lab of John F.
Alderete, Ph.D. at The University of Texas Health Science Center
at San Antonio. Specific terms of the deal were not announced,
but include milestone payments and royalties.
Trichomonas Vaginalis infects both men and women and is the most
prevalent non-viral STD in the world, with an estimated 350 million
women alone affected each year. The FDA-approved Xenotope diagnostic
test is the only rapid test available for diagnosing Trichomonas
infections and is extremely accurate. Xenotope, founded just
2 years ago in San Francisco, has a business and scientific focus
around products resulting from molecular biology and infectious
disease research in areas of unmet medical needs where it can
be a market leader. According to Paul Castella, Ph.D., CEO and
co-founder, "The richness of The University of Texas Health
Science Center at San Antonio's infectious disease research and
cooperative spirit in commercializing its intellectual properties
encouraged us to move to San Antonio. We hope to play a major
role in expanding the technology base here. This agreement is
a pivotal event in our young company's growth, and I believe
establishes an excellent foundation to reach our objectives."
Contact: Paul Castella, Ph.D.
Genzyme, founded in 1981, is a public company with 5,500 employees,
world-wide operations and corporate offices in Cambridge, Massachusetts.
It is composed of 3 divisions: (1) Genzyme Biosurgery, serving
the market for specialized biotechnology products used in surgery;
(2) Genzyme General, specializing in diagnostic products and
therapeutics; and (3) Genzyme Molecular Oncology, which develops
breakthrough solutions in the treatment of cancer. Product revenues
exceeded $1 billion in 2001 and 2002.
Xenotope Diagnostics, Inc.
San Antonio Technology Center
3463 Magic Drive, Suite T-2
San Antonio, Texas 78229
(210) 582-5838 - PHONE
(210) 582-5839 FAX
|send comments or questions to webmaster.